No Data
No Data
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
10-Q: Quarterly report
No Data